Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | AGXT | P21549 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12885589 | 0.94 | RAB9A (0.39) | IDO1CYP1A2CYP2A6TAAR1TSHR | |
| SCHEMBL1470968 | 0.90 | ESR1 (0.33) | — | |
| SCHEMBL31019832 | 0.79 | HRH3 (0.44) | TAAR1HRH3CA1CA2CA9 | |
| SCHEMBL2011093 | 0.79 | TSHR (0.42) | TSHRACHETP53BCHEDAO | |
| SCHEMBL706086 | 0.78 | TAAR1 (0.44) | IDO1CYP1A2TAAR1TSHRTP53 | |
| SCHEMBL2011622 | 0.76 | NR1H2 (0.35) | — | |
| SCHEMBL3683269 | 0.76 | TAAR1 (0.45) | IDO1TAAR1TSHRAGXTRAB9A | |
| SCHEMBL702989 | 0.74 | ALDH1A1 (0.44) | TSHRTDP1TP53MAPTCA1 | |
| SCHEMBL27789336 | 0.74 | TAAR1 (0.47) | IDO1TAAR1ACHEDAOHRH3 | |
| SCHEMBL9508708 | 0.74 | IDO1 (0.50) | IDO1CYP1A2CYP2A6TAAR1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1527038-B1 | PROCESS FOR THE CARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUDS | LUCITE INT UK LTD (GB) | 2010-03-17 | — | — | EP | disclosed |
| US-7265240-B2 | With CO in the presence of a source of hydroxyl groups (water or an alcohol) and a catalyst obtained by combining a Group VIII metal or a compound thereof and a bidentate phosphine, e.g., tri(dibenzylideneacetone)di-palladium | LUCITE INTERNATIONAL UK LIMITED (GB) | 2007-09-04 | — | — | US | disclosed |
| US-20060122435-A1 | Process for the carbonylation of ethylenically unsaturated compounds | LUCITE INTERNATIONAL UK LIMITED (GB) | 2006-06-08 | — | — | US | disclosed |
| EP-1527038-A1 | PROCESS FOR THE CARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUDS | Lucite International UK Limited (GB) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004014834-A1 | PROCESS FOR THE CARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUDS | LUCITE INTERNATIONAL UK LIMITED (GB) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122435-A1 | Process for the carbonylation of ethylenically unsaturated compounds | CYC1, CYCS, COX5A | IDO1 3323/4885CYP1A2 144/4885CYP2A6 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.